Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lichen planus (LP) is an inflammatory skin disease of unknown etiology. Glutamine promotes protein and collagen synthesis, imparts immunity, and maintains the alimentary canal mucosa structure.
Lichen planus (LP) is an inflammatory skin disease of unknown etiology. Recently, increased oxidative stress has been implicated in the pathogenesis of erosive oral lichen planus (EOLP). Glutamine is a source of energy for fibroblasts, immunocompetent cells, and intestinal epithelial cells involved in collagen production. It promotes protein and collagen synthesis, imparts immunity, and maintains the alimentary canal mucosa structure.
The aim of this study is to evaluate the effect of Glutamine combined with topical corticosteroid in the treatment of oral erosive LP.
Thirty patients with a confirmed clinical and histopathologic diagnosis of OLP recruited in this study and divided into 2 equal groups, each consisting of 15 subjects. Group 1 consists of patients treated with topical steroids plus antifungal (conventional therapy); Group 2 consists of patients treated with Glutamine combined with topical steroids plus antifungal.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| conventional therapy | Active Comparator | topical corticosteroid plus antifungal |
|
| Glutamine with a topical corticosteroid plus antifungal | Experimental | Glutamine therapy in combination with a topical corticosteroid plus antifungal |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glutamine Cap/Tab | Drug | Glutamine Capsules: One capsule three times daily on an empty stomach for one month |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in oral lichen planus lesions severity | Mucosal lesion severity score 0: no lesion score 1: white lesion score 2:atrophy/erosion intermixed or not with white lesion score 3: ulceration intermixed or not with white lesion | at baseline, 1 months and 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in pain level | Pain score score 0= no pain score 1= mild score 2= moderate score 3= severe | at baseline, 1 months and 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Outpatient Clinic of Oral medicine Department, Faculty of Dentistry, Alexandria University, Egypt | Alexandria | Egypt |
Not provided
| ID | Term |
|---|---|
| D014221 | Triamcinolone |
| C056627 | Orabase |
| ID | Term |
|---|---|
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Miconazole Oral gel | Drug | Miconazole oral gel: applied three to four times daily for three weeks |
|
| Kenacort in orabase | Drug | Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached |
|
| D011083 |
| Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |